Immutep to Present Efti Clinical Trial Data at CTOS 2026 and ESMO Immuno-Oncology Congresses

Manish Choudhary

05 November 2026 03:14 PM AEDT

Immutep to Present Efti Clinical Trial Data at CTOS 2026 and ESMO Immuno-Oncology Congresses

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Immutep Limited (ASX:IMM), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, has announced that data from two clinical trials of its first-in-class MHC Class II agonist eftilagimod alfa (efti) will be presented in poster sessions at two international medical congresses in November and December 2026.

Key Points

Survival data from the investigator-initiated EFTISARC-NEO Phase II trial will be presented at the CTOS 2026 Annual Meeting in Seoul, South Korea, on 19 November 2026
Final median overall survival results from Part B of the TACTI-003 Phase IIb trial will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026 in London on 14 December 2026
The EFTISARC-NEO presentation covers efti in combination with pembrolizumab and radiotherapy in neoadjuvant treatment of patients with resectable soft tissue sarcoma
The TACTI-003 Part B presentation covers efti in combination with pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma in patients with a PD-L1 combined positive score of less than 1

EFTISARC-NEO Presentation at CTOS 2026 Annual Meeting

The CTOS 2026 Annual Meeting will be held from 18 to 21 November 2026 in Seoul, South Korea. Immutep's poster, titled "Disease Free Survival (DFS) in Patients with Resectable Soft Tissue Sarcoma (STS) from Eftisarc-Neo Phase II Trial of Neoadjuvant Eftilagimod Alfa (Efti), Pembrolizumab and Radiotherapy (RTH)," is scheduled for a Poster Discussion session on 19 November 2026 at 4:30 p.m. KST. The first author is Pawel Sobczuk, MD PhD, from the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. The trial is registered under NCT06128863.

TACTI-003 Final Results at ESMO Immuno-Oncology Congress 2026

The ESMO Immuno-Oncology & Advanced Therapies Congress 2026 will be held from 14 to 16 December 2026 in London, United Kingdom. Immutep's poster, titled "Eftilagimod Alfa and Pembrolizumab in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with PD-L1 CPS <1: Final Results from the TACTI-003 Study," is scheduled for a Poster Display session on 14 December 2026 at 17:30 GMT. The first author is Claus A. Kristensen, MD PhD, from Copenhagen University Hospital in Copenhagen, Denmark. The trial is registered under NCT04811027.

Company Background and Product Portfolio

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3). Its product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. The company is listed on both the ASX and NASDAQ under the tickers IMM and IMMP respectively. The filing states that presentation data will be made available on Immutep's Posters & Publications page following each presentation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.